Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ankyrin repeat domain 18C, pseudogene (ANKRD18CP) is classified as a **pseudogene**, meaning it is a DNA segment that closely resembles a functional gene but does not code for a protein product due to accumulated disabling mutations[1][2][3][4]. ANKRD18CP is found on human chromosome 9, but its precise biological function remains unknown, as is typical for pseudogenes[5]. Although it does not produce a functional protein, methylation of the ANKRD18CP region has been studied as a potential epigenetic biomarker for cervical pre-cancer screening[5]. There is *no evidence* suggesting that ANKRD18CP serves as a therapeutic target (such as a receptor, enzyme, transporter, or similar class), nor are there any drugs known to target this pseudogene[1][5]. Pseudogenes in general can regulate gene expression in subtle ways or provide information about evolutionary history, but clinical or pharmacological functions have not been established for ANKRD18CP[2][3][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ankyrin repeat domain 18C, pseudogene (ANKRD18CP).